Research programme: menin-MLL inhibitors - Kura Oncology

Drug Profile

Research programme: menin-MLL inhibitors - Kura Oncology

Alternative Names: KO 381; KO 382; KO 539; MI 463; MI 503

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer Kura Oncology; University of Michigan
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Menin inhibitors; Protein interaction domain and motif inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leukaemia

Most Recent Events

  • 14 Dec 2017 KO 539 is still in preclinical trials for Leukaemia in USA (PO)
  • 01 Dec 2016 Pharmacodynamics data from preclinical trials in Leukaemia presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC 2016)
  • 29 Nov 2016 Pharmacodynamics data from a preclinical study in Leukaemia presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top